Document is current
Any future updates will be listed below
-
Authors
Becking, Anne-Marie L. https://orcid.org/0009-0004-2942-9385
van de Mortel, Johannes P. M. https://orcid.org/0000-0002-9956-744X
Tomkins, Oliver https://orcid.org/0000-0002-1059-2906
Flinsenberg, Thijs W. H.
Japzon, Nicole
Kersten, Marie José https://orcid.org/0000-0002-8904-3802
Khwaja, Jahanzaib https://orcid.org/0000-0002-4993-7828
Kuipers, Saskia
Levenga, Henriette
McKeague, Sean
Opat, Stephen https://orcid.org/0000-0002-0308-6458
Salvaris, Ross T.
Seif, Sherif
Thomas, Sheeba K.
Vrancken, Alexander F. J. E. https://orcid.org/0000-0003-4649-6534
D’Sa, Shirley https://orcid.org/0000-0003-0840-3499
Minnema, Monique C. https://orcid.org/0000-0002-3139-8379
Vos, Josephine M. I. https://orcid.org/0000-0003-3229-9556
-
Funding
Funding for this research was provided by:
This work was supported by Mr. R. de Jong via the Amsterdam UMC foundation
- License Information
-
More Information
Article History
Received: 13 December 2024
Revised: 12 March 2025
Accepted: 19 March 2025
First Online: 31 March 2025
Competing interests
: MJK has received research support from Kite/Gilead; honoraria for advisory boards and/or presentations from Beigene, Kite/Gilead, Miltenyi Biotec, Novartis, Adicet Bio, Mustang Bio, Roche, and BMS (all to institution); and travel support for conferences from Beigene, Roche, and BMS. SO has acted as a consultant/advisor for AbbVie, AstraZeneca, BeiGene, Janssen, Gilead, Merck and Bristol Myers Squibb; his institution has received research funding from AbbVie, BeiGene, Janssen, Gilead, Pharmacyclics, Roche, and Ipsen; and has received honoraria from AbbVie, AstraZeneca, BeiGene, Janssen, Gilead, Merck and Bristol Myers Squibb. RTS received honoraria from Janssen, AbbVie, Roche, AstraZeneca, BeiGene. SKT has received research support from Sanofi, Bristol Myers Squibb, Cellectar Biosciences, and Abbvie, and has served on the advisory board of Cellectar Biosciences and Mustang Bio. SD’S has received speaker fees, honoraria, congress support, research support and is on the advisory board for Beigene; advisory board for Sanofi, and Cellectar. MCM received research funding from Beigene, Speakers fee from Janssen Cilag, Siemens, and Springer Healthcare, and Consultancy fee from Janssen Cilag, Pfizer, BMS, GSK, and Hospitality Janssen Cilag. JMIV has received the following as institutional honoraria: research support from Beigene and AbbVie/Genmab; advisory board/consultancy fees from Sanofi and Janssen; and speaker fees from BMS, Sanofi, Beigene, Novartis, and Amgen. ALB, JPMvdM, OT, TWHF, NJ, JK, SK, HL, SM, SS, and AFJEV declare no potential competing interests.
